Precancerous Condition, Stage 0 Melanoma, Stage II Melanoma, Stage I Melanoma
Conditions
Brief summary
The use of lovastatin may slow disease progression in patients at high risk of melanoma. It is not yet known whether lovastatin is more effective than a placebo in treating patients at high risk of melanoma. This randomized phase II trial studies how well giving lovastatin or placebo works in treating patients at high risk of melanoma.
Detailed description
PRIMARY OBJECTIVES: I. To evaluate the primary endpoint of the trial, by analysis of histopathologic regression of atypical nevi in response to a 6-month trial of oral (PO) lovastatin vs. placebo in subjects with atypical nevi. SECONDARY OBJECTIVES: I. To evaluate clinical regression of atypical nevi in the lovastatin vs. placebo group. II. To evaluate the secondary endpoint of changes in nevi numbers on subjects' backs in the lovastatin vs. placebo groups. III. To evaluate a number of molecular biomarkers as secondary endpoints in the lovastatin vs. placebo groups. IV. To evaluate the correlation of serum markers known to be affected by lovastatin with the endpoints chosen above. V. To evaluate the safety and tolerability of the dosing regimen, and the dose escalation. OUTLINE: Patients are randomized into 1 of 2 treatment arms per group. ARM I: Patients (with two matched nevi OR one large nevi) receive lovastatin PO once daily (QD) for up to 6 months in the absence of disease progression or unacceptable toxicity. ARM II: Patients (with two matched nevi OR one large nevi) receive placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 2 weeks.
Interventions
DRUGlovastatin
Given PO
OTHERplacebo
Given PO
PROCEDUREbiopsy
Correlative studies
PROCEDURElaboratory biomarker analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Presence of at least 2 clinically atypical nevi on the body that are reasonably matched in regards to level of clinical atypia, or one atypical mole and another atypical mole \>= 8 mm in diameter (for this pair the two moles do not have to be closely matched and only one of them must be \>= 8 mm in diameter) * A history of melanoma is not required for study entry * Patients with completely resected stage I or II who have not received adjuvant therapy in the past 3 months * Eastern Cooperative Oncology Group (ECOG) performance status of 1 or better (Karnofsky \> 70%) * Leukocytes \>= 3,000/uL * Absolute neutrophil count \>= 1,500/uL * Platelets \>= 100,000/uL * Total bilirubin within normal institutional limits * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \[SGPT\]) =\< 2.5 X within normal limits * Creatinine within normal institutional limits * Ability to understand and the willingness to sign the written informed consent * Subjects willing and able to participate for the full duration of the study * For women of child-bearing potential (women are considered not of childbearing potential if they are at least 2 years post-menopausal and/or surgically sterile), she: * has been using adequate contraception (abstinence, intrauterine device \[IUD\], birth control pills, or spermicidal gel with diaphragm or condom) since her last menses and will use adequate contraception during the study * is not lactating, and * has had a documented negative serum pregnancy test within 30 days prior to the first dose of study medication Should a woman become pregnant or suspect she is pregnant while participating in this study, she will be taken off study and be advised to inform her treating physician immediately; a telephone follow-up with the subject post-delivery will be completed to obtain outcome of pregnancy * Men partnered with a female of child-bearing age must agree to use adequate contraception while on the study (i.e. abstinence, IUD, birth control pills, or spermicidal gel with diaphragm or condom)
Exclusion criteria
* Subjects with untreated melanoma of any stage or locally advanced (\>= 4 mm in Breslow's thickness) or metastatic (stage III or IV) melanoma; subjects with melanoma may be considered for trial after complete resection of Stage I or II melanoma and those who have declined or are ineligible to go on any available adjuvant clinical trials known to the investigators or the subjects are eligible * Subjects who are on adjuvant therapy or experimental therapy for melanoma currently or within the last 3 months prior to enrollment into this study * Subjects currently or within the last three months before enrollment on lipid lowering agents of any type * History of allergic reactions attributed to compounds of similar chemical or biologic composition to lovastatin * Clinically significant unrelated systemic illness * Subjects with any medical or psychosocial condition that, in the opinion of the investigator, could jeopardize his/her participation in and compliance with the study * Subjects may not be receiving any other investigational agents * Pregnant or breast feeding females, or females of child bearing age not using a reliable method of contraception (use of lovastatin is contraindicated in pregnancy) * Subjects who have been diagnosed with malignancies other than cutaneous melanoma, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma within 5 years of study entry, unless they: * are currently without evidence of disease * have not received treatment for invasive malignancy in the last 6 months * have no current or planned therapy, and * have an expected disease-free survival of at least 5 years from study entry * Chronic use of: itraconazole; ketoconazole; erythromycin; clarithromycin; telithromycin; human immunodeficiency virus (HIV) protease inhibitors; nefazodone; cyclosporine; gemfibrozil and other fibrates; danazol; amiodarone (amiodarone hydrochloride); verapamil; coumarin anticoagulants; niacin (nicotinic acid) (\>= 1 g/day); or large quantities of grapefruit juice (\> l quart daily) * Subjects with a history of coronary artery disease or stroke
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 1's Evaluation | From baseline up to 24 weeks | The level of atypia will be graded in a standard fashion which leads to seven levels of atypia, with zero being no atypia and six being a melanoma. For each patient, the change from baseline in the level of atypia was calculated. Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers. |
| Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 2's Evaluation | From baseline up to 24 weeks | The level of atypia will be graded in a standard fashion which leads to seven levels of atypia, with zero being no atypia and six being a melanoma. For each patient, the change from baseline in the level of atypia was calculated. Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Regression of Atypical Moles - Average of Three Reviewers' Evaluations | From baseline up to 24 weeks | From close-up photos of target atypical nevi, lesions will be graded clinically. After unblinding of pre- or post-treatment status for photos, the grading score was as follows: 1= Post-treatment (Post-TX) photo shows a complete resolution of atypia relative to pre-treatment (Pre-TX) photo, 2 = Post-TX photo shows a strong lessening of atypia relative to Pre-TX photo, 3 = Post-TX photo shows a mild lessening of atypia relative to Pre-TX photo, 4 = Post-TX and Pre-TX photos show same degree of atypia, 5 = Pre-TX photo shows a mild lessening of atypia relative to Post-TX photo, 6 = Pre-TX photo shows a strong lessening of atypia relative to Post-TX photo, 7 = Pre-TX photo shows a complete resolution of atypia relative to Post-TX photo. The Wilcoxon rank sum test will be applied to compare the scores for patients treated with placebo vs. those treated with lovastatin. |
| Total Nevus Number on Patient's Back - Combined Three Reviewers' Evaluations | From baseline up to 24 weeks | Assessed by photos of subjects' back pre and post treatment. These photos will be used to count, by blinded evaluators, the number of nevi on the back pre and post therapy. |
| Serum and Molecular Biomarkers - HIF1alpha: Pathologist 3's Evaluation | From baseline up to 24 weeks | HIF1alpha expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated. |
| Serum and Molecular Biomarkers - (e)-Cadherin: Pathologist 3's Evaluation | From baseline up to 24 weeks | (e)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated. |
| Serum and Molecular Biomarkers - (n)-Cadherin: Pathologist 3's Evaluation | From baseline up to 24 weeks | (n)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated. |
| Serum and Molecular Biomarkers - p21 (WAF1/CIP1): Pathologist 3's Evaluation | From baseline up to 24 weeks | p21 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated. |
| Serum and Molecular Biomarkers - Ki-67: Pathologist 3's Evaluation | From baseline up to 24 weeks | Ki-67 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated. |
| Serum and Molecular Biomarkers - HIF1alpha: Pathologist 4's Evaluation | From baseline up to 24 weeks | HIF1alpha expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated. |
| Serum and Molecular Biomarkers - (e)-Cadherin: Pathologist 4's Evaluation | From baseline up to 24 weeks | (e)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated. |
| Serum and Molecular Biomarkers - (n)-Cadherin: Pathologist 4's Evaluation | From baseline up to 24 weeks | (n)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated. |
| Serum and Molecular Biomarkers - VEGF: Pathologist 4's Evaluation | From baseline up to 24 weeks | VEGF expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated. |
| Serum and Molecular Biomarkers - VEGF: Pathologist 3's Evaluation | From baseline up to 24 weeks | VEGF expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated. |
| Serum and Molecular Biomarkers - p21 (WAF1/CIP1): Pathologist 4's Evaluation | From baseline up to 24 weeks | p21 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated. |
| Serum and Molecular Biomarkers - Ki-67: Pathologist 4's Evaluation | From baseline up to 24 weeks | Ki-67 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated. |
| Change in Cholesterol (mg/dL) From Baseline After Treatment | Baseline up to 24 weeks | — |
| Change in LDL (mg/dL) From Baseline After Treatment | Baseline up to 24 weeks | — |
| Change in HDL (mg/dL) From Baseline After Treatment | Baseline up to 24 weeks | — |
| Change in Triglycerides (mg/dL) From Baseline After Treatment | Baseline up to 24 weeks | — |
| Change in SGOT/AST (U/L) From Baseline After Treatment | Baseline up to 24 weeks | — |
| Change in SGOT/ALT (U/L) From Baseline After Treatment | Baseline up to 24 weeks | — |
| Change in CPK (U/L) From Baseline After Treatment | Baseline up to 24 weeks | — |
| Change in C-reactive Protein (mg/dL) From Baseline After Treatment | Baseline up to 24 weeks | — |
| At Least 1 Study-related Adverse Event Reported During the Study | Baseline up to 26 weeks | All participants will be evaluable for toxicity from the time of their informed consent. Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0. |
| Serum and Molecular Biomarkers - RelA: Pathologist 4's Evaluation | From baseline up to 24 weeks | RelA expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated. |
| Serum and Molecular Biomarkers - RelA: Pathologist 3's Evaluation | From baseline up to 24 weeks | RelA expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Two Matched Nevi Group-Lovastatin Patients with two matched nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies | 34 |
| Two Matched Nevi Group-Placebo Patients with two matched nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies | 32 |
| One Large Nevi Group-Lovastatin Patients with one large nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
lovastatin: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies | 7 |
| One Large Nevi Group-Placebo Patients with one large nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
placebo: Given PO
biopsy: Correlative studies
laboratory biomarker analysis: Correlative studies | 7 |
| Total | 80 |
Baseline characteristics
| Characteristic | Two Matched Nevi Group-Lovastatin | Two Matched Nevi Group-Placebo | One Large Nevi Group-Lovastatin | One Large Nevi Group-Placebo | Total |
|---|---|---|---|---|---|
| Age, Continuous | 42.82 years STANDARD_DEVIATION 10.96 | 42.16 years STANDARD_DEVIATION 11.28 | 45.71 years STANDARD_DEVIATION 10.98 | 36.29 years STANDARD_DEVIATION 11.98 | 42.24 years STANDARD_DEVIATION 11.16 |
| Region of Enrollment United States | 34 participants | 32 participants | 7 participants | 7 participants | 80 participants |
| Sex: Female, Male Female | 21 Participants | 20 Participants | 2 Participants | 2 Participants | 45 Participants |
| Sex: Female, Male Male | 13 Participants | 12 Participants | 5 Participants | 5 Participants | 35 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 27 / 34 | 25 / 32 | 4 / 7 | 5 / 7 |
| serious Total, serious adverse events | 1 / 34 | 2 / 32 | 0 / 7 | 1 / 7 |
Outcome results
Primary
Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 1's Evaluation
The level of atypia will be graded in a standard fashion which leads to seven levels of atypia, with zero being no atypia and six being a melanoma. For each patient, the change from baseline in the level of atypia was calculated. Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers.
Time frame: From baseline up to 24 weeks
Population: Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Two Matched Nevi Group - Lovastatin | Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 1's Evaluation | 0.50 score | Standard Deviation 1.1 |
| Two Matched Nevi Group - Placebo | Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 1's Evaluation | -0.12 score | Standard Deviation 1.33 |
Primary
Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 2's Evaluation
The level of atypia will be graded in a standard fashion which leads to seven levels of atypia, with zero being no atypia and six being a melanoma. For each patient, the change from baseline in the level of atypia was calculated. Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers.
Time frame: From baseline up to 24 weeks
Population: Only the Two Matched Nevi Group - Lovastatin and Two Matched Nevi Group - Placebo data were used and analyzed for the primary outcome. One-Large Nevi Group - Lovastatin and One-Large Nevi Group - Placebo sample data were not used or analyzed due to insufficient numbers.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Two Matched Nevi Group - Lovastatin | Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 2's Evaluation | 0.17 score | Standard Deviation 1.81 |
| Two Matched Nevi Group - Placebo | Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 2's Evaluation | 0.04 score | Standard Deviation 1.95 |
Secondary
At Least 1 Study-related Adverse Event Reported During the Study
All participants will be evaluable for toxicity from the time of their informed consent. Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0.
Time frame: Baseline up to 26 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Two Matched Nevi Group - Lovastatin | At Least 1 Study-related Adverse Event Reported During the Study | Yes | 14 participants |
| Two Matched Nevi Group - Lovastatin | At Least 1 Study-related Adverse Event Reported During the Study | No | 27 participants |
| Two Matched Nevi Group - Placebo | At Least 1 Study-related Adverse Event Reported During the Study | Yes | 11 participants |
| Two Matched Nevi Group - Placebo | At Least 1 Study-related Adverse Event Reported During the Study | No | 28 participants |
Secondary
Change in Cholesterol (mg/dL) From Baseline After Treatment
Time frame: Baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Change in Cholesterol (mg/dL) From Baseline After Treatment | -27.25 mg/dL |
| Two Matched Nevi Group - Placebo | Change in Cholesterol (mg/dL) From Baseline After Treatment | -3.77 mg/dL |
Secondary
Change in CPK (U/L) From Baseline After Treatment
Time frame: Baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Change in CPK (U/L) From Baseline After Treatment | 20.94 U/L |
| Two Matched Nevi Group - Placebo | Change in CPK (U/L) From Baseline After Treatment | 9.1 U/L |
Secondary
Change in C-reactive Protein (mg/dL) From Baseline After Treatment
Time frame: Baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Change in C-reactive Protein (mg/dL) From Baseline After Treatment | -0.3 mg/dL |
| Two Matched Nevi Group - Placebo | Change in C-reactive Protein (mg/dL) From Baseline After Treatment | -0.11 mg/dL |
Secondary
Change in HDL (mg/dL) From Baseline After Treatment
Time frame: Baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Change in HDL (mg/dL) From Baseline After Treatment | -1.42 mg/dL |
| Two Matched Nevi Group - Placebo | Change in HDL (mg/dL) From Baseline After Treatment | -2.63 mg/dL |
Secondary
Change in LDL (mg/dL) From Baseline After Treatment
Time frame: Baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Change in LDL (mg/dL) From Baseline After Treatment | -25.28 mg/dL |
| Two Matched Nevi Group - Placebo | Change in LDL (mg/dL) From Baseline After Treatment | -0.4 mg/dL |
Secondary
Change in SGOT/ALT (U/L) From Baseline After Treatment
Time frame: Baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Change in SGOT/ALT (U/L) From Baseline After Treatment | 5.61 U/L |
| Two Matched Nevi Group - Placebo | Change in SGOT/ALT (U/L) From Baseline After Treatment | 2.93 U/L |
Secondary
Change in SGOT/AST (U/L) From Baseline After Treatment
Time frame: Baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Change in SGOT/AST (U/L) From Baseline After Treatment | 3.42 U/L |
| Two Matched Nevi Group - Placebo | Change in SGOT/AST (U/L) From Baseline After Treatment | -0.75 U/L |
Secondary
Change in Triglycerides (mg/dL) From Baseline After Treatment
Time frame: Baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Change in Triglycerides (mg/dL) From Baseline After Treatment | 1.21 mg/dL |
| Two Matched Nevi Group - Placebo | Change in Triglycerides (mg/dL) From Baseline After Treatment | 1.65 mg/dL |
Secondary
Clinical Regression of Atypical Moles - Average of Three Reviewers' Evaluations
From close-up photos of target atypical nevi, lesions will be graded clinically. After unblinding of pre- or post-treatment status for photos, the grading score was as follows: 1= Post-treatment (Post-TX) photo shows a complete resolution of atypia relative to pre-treatment (Pre-TX) photo, 2 = Post-TX photo shows a strong lessening of atypia relative to Pre-TX photo, 3 = Post-TX photo shows a mild lessening of atypia relative to Pre-TX photo, 4 = Post-TX and Pre-TX photos show same degree of atypia, 5 = Pre-TX photo shows a mild lessening of atypia relative to Post-TX photo, 6 = Pre-TX photo shows a strong lessening of atypia relative to Post-TX photo, 7 = Pre-TX photo shows a complete resolution of atypia relative to Post-TX photo. The Wilcoxon rank sum test will be applied to compare the scores for patients treated with placebo vs. those treated with lovastatin.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Two Matched Nevi Group - Lovastatin | Clinical Regression of Atypical Moles - Average of Three Reviewers' Evaluations | 4.03 score | Standard Deviation 0.26 |
| Two Matched Nevi Group - Placebo | Clinical Regression of Atypical Moles - Average of Three Reviewers' Evaluations | 3.98 score | Standard Deviation 0.31 |
p-value: 0.61Wilcoxon (Mann-Whitney)
Secondary
Serum and Molecular Biomarkers - (e)-Cadherin: Pathologist 3's Evaluation
(e)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Serum and Molecular Biomarkers - (e)-Cadherin: Pathologist 3's Evaluation | 0.67 percentage of cells that are positive |
| Two Matched Nevi Group - Placebo | Serum and Molecular Biomarkers - (e)-Cadherin: Pathologist 3's Evaluation | -7.37 percentage of cells that are positive |
Secondary
Serum and Molecular Biomarkers - (e)-Cadherin: Pathologist 4's Evaluation
(e)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Serum and Molecular Biomarkers - (e)-Cadherin: Pathologist 4's Evaluation | 4.23 percentage of cells that are positive |
| Two Matched Nevi Group - Placebo | Serum and Molecular Biomarkers - (e)-Cadherin: Pathologist 4's Evaluation | -7.40 percentage of cells that are positive |
Secondary
Serum and Molecular Biomarkers - HIF1alpha: Pathologist 3's Evaluation
HIF1alpha expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Serum and Molecular Biomarkers - HIF1alpha: Pathologist 3's Evaluation | 0.05 percentage of cells that are positive |
| Two Matched Nevi Group - Placebo | Serum and Molecular Biomarkers - HIF1alpha: Pathologist 3's Evaluation | -0.32 percentage of cells that are positive |
Secondary
Serum and Molecular Biomarkers - HIF1alpha: Pathologist 4's Evaluation
HIF1alpha expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Serum and Molecular Biomarkers - HIF1alpha: Pathologist 4's Evaluation | -0.04 percentage of cells that are positive |
| Two Matched Nevi Group - Placebo | Serum and Molecular Biomarkers - HIF1alpha: Pathologist 4's Evaluation | -0.04 percentage of cells that are positive |
Secondary
Serum and Molecular Biomarkers - Ki-67: Pathologist 3's Evaluation
Ki-67 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Serum and Molecular Biomarkers - Ki-67: Pathologist 3's Evaluation | 0.73 percentage of cells that are positive |
| Two Matched Nevi Group - Placebo | Serum and Molecular Biomarkers - Ki-67: Pathologist 3's Evaluation | 0.50 percentage of cells that are positive |
Secondary
Serum and Molecular Biomarkers - Ki-67: Pathologist 4's Evaluation
Ki-67 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Serum and Molecular Biomarkers - Ki-67: Pathologist 4's Evaluation | 0.57 percentage of cells that are positive |
| Two Matched Nevi Group - Placebo | Serum and Molecular Biomarkers - Ki-67: Pathologist 4's Evaluation | 0.28 percentage of cells that are positive |
Secondary
Serum and Molecular Biomarkers - (n)-Cadherin: Pathologist 3's Evaluation
(n)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Serum and Molecular Biomarkers - (n)-Cadherin: Pathologist 3's Evaluation | 5.91 percentage of cells that are positive |
| Two Matched Nevi Group - Placebo | Serum and Molecular Biomarkers - (n)-Cadherin: Pathologist 3's Evaluation | -9.17 percentage of cells that are positive |
Secondary
Serum and Molecular Biomarkers - (n)-Cadherin: Pathologist 4's Evaluation
(n)-cadherin expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Serum and Molecular Biomarkers - (n)-Cadherin: Pathologist 4's Evaluation | 4.24 percentage of cells that are positive |
| Two Matched Nevi Group - Placebo | Serum and Molecular Biomarkers - (n)-Cadherin: Pathologist 4's Evaluation | -3.52 percentage of cells that are positive |
Secondary
Serum and Molecular Biomarkers - p21 (WAF1/CIP1): Pathologist 3's Evaluation
p21 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Serum and Molecular Biomarkers - p21 (WAF1/CIP1): Pathologist 3's Evaluation | 1.00 percentage of cells that are positive |
| Two Matched Nevi Group - Placebo | Serum and Molecular Biomarkers - p21 (WAF1/CIP1): Pathologist 3's Evaluation | 1.18 percentage of cells that are positive |
Secondary
Serum and Molecular Biomarkers - p21 (WAF1/CIP1): Pathologist 4's Evaluation
p21 expression was assessed via nuclear staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Serum and Molecular Biomarkers - p21 (WAF1/CIP1): Pathologist 4's Evaluation | 2.05 percentage of cells that are positive |
| Two Matched Nevi Group - Placebo | Serum and Molecular Biomarkers - p21 (WAF1/CIP1): Pathologist 4's Evaluation | -0.13 percentage of cells that are positive |
Secondary
Serum and Molecular Biomarkers - RelA: Pathologist 3's Evaluation
RelA expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Serum and Molecular Biomarkers - RelA: Pathologist 3's Evaluation | 0.83 percentage of cells that are positive |
| Two Matched Nevi Group - Placebo | Serum and Molecular Biomarkers - RelA: Pathologist 3's Evaluation | -1.25 percentage of cells that are positive |
Secondary
Serum and Molecular Biomarkers - RelA: Pathologist 4's Evaluation
RelA expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Serum and Molecular Biomarkers - RelA: Pathologist 4's Evaluation | 3.73 percentage of cells that are positive |
| Two Matched Nevi Group - Placebo | Serum and Molecular Biomarkers - RelA: Pathologist 4's Evaluation | -3.44 percentage of cells that are positive |
Secondary
Serum and Molecular Biomarkers - VEGF: Pathologist 3's Evaluation
VEGF expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Serum and Molecular Biomarkers - VEGF: Pathologist 3's Evaluation | 4.81 percentage of cells that are positive |
| Two Matched Nevi Group - Placebo | Serum and Molecular Biomarkers - VEGF: Pathologist 3's Evaluation | -0.63 percentage of cells that are positive |
Secondary
Serum and Molecular Biomarkers - VEGF: Pathologist 4's Evaluation
VEGF expression was assessed via cytoplasmic staining, and the change in the percentage of positive stained cells from baseline to 24 weeks is calculated.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Two Matched Nevi Group - Lovastatin | Serum and Molecular Biomarkers - VEGF: Pathologist 4's Evaluation | -1.83 percentage of cells that are positive |
| Two Matched Nevi Group - Placebo | Serum and Molecular Biomarkers - VEGF: Pathologist 4's Evaluation | -2.24 percentage of cells that are positive |
Secondary
Total Nevus Number on Patient's Back - Combined Three Reviewers' Evaluations
Assessed by photos of subjects' back pre and post treatment. These photos will be used to count, by blinded evaluators, the number of nevi on the back pre and post therapy.
Time frame: From baseline up to 24 weeks
Population: One Large Nevi Group-Lovastatin and Two Matched Nevi Group-Lovastatin arms are combined into the Lovastatin arm while One Large Nevi Group-Placebo and Two Matched Nevi Group-Placebo arms are combined into the Placebo arm. The total number of participants who have complete data are analyzed in this outcome measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Two Matched Nevi Group - Lovastatin | Total Nevus Number on Patient's Back - Combined Three Reviewers' Evaluations | Fewer nevi after the treatment | 4 pairs of photos |
| Two Matched Nevi Group - Lovastatin | Total Nevus Number on Patient's Back - Combined Three Reviewers' Evaluations | Same number of nevi after treatment | 64 pairs of photos |
| Two Matched Nevi Group - Lovastatin | Total Nevus Number on Patient's Back - Combined Three Reviewers' Evaluations | More nevi after the treatment | 1 pairs of photos |
| Two Matched Nevi Group - Placebo | Total Nevus Number on Patient's Back - Combined Three Reviewers' Evaluations | Fewer nevi after the treatment | 3 pairs of photos |
| Two Matched Nevi Group - Placebo | Total Nevus Number on Patient's Back - Combined Three Reviewers' Evaluations | Same number of nevi after treatment | 67 pairs of photos |
| Two Matched Nevi Group - Placebo | Total Nevus Number on Patient's Back - Combined Three Reviewers' Evaluations | More nevi after the treatment | 7 pairs of photos |